An interventional study of Miyarisan-BM (Clostridium Butyricum Miyairi) in Clostridium Butyricum Miyairi and Parkinson Disease, sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-08-12.
Sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Parkinson Disease with a site in Taiwan — 33 open to participants now, 37 under way, 1 of them phase 3. Parkinson Disease · Taiwan.
Among the 121 studies in Parkinson Disease with a site in Taiwan, this one is the 5th largest by planned enrollment of the 99 interventional ones that give a count, is one of 9 that started in 2023, is one of 72 with no phase, reaches primary completion later than 17 of the 36 other live ones, and was the 97th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →33 of the 121 studies in Parkinson Disease with a site in Taiwan are open now. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 18+
Serina Therapeutics · Sites in Taiwan, United States, Australia
Ages 40–80
Hoffmann-La Roche · Sites in Taiwan, United States, Australia and 14 more countries
Ages 50–85
National Taiwan University Hospital · Sites in Taiwan
Ages 18+ · Healthy volunteers
National Taiwan University Hospital · Sites in Taiwan
Ages 18–80
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 20 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 9 · Phase 4 2
First in 2005; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 55 across the 99 interventional studies, 92 across the 22 observational. Of the 58 that completed or were terminated, 9 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 121 have an industry lead sponsor. The 10 most frequent:
Kaohsiung Medical University Chung-Ho Memorial Hospital is the lead sponsor of 292 studies on the registry; 59 are open to participants now.
Kaohsiung Medical University Chung-Ho Memorial Hospital has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
11 of the studies in Parkinson Disease with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06548256Kaohsiung Medical University Chung-Ho Memorial HospitalThe Clinical Application of Clostridium Butyricum Miyairisan for Motor and Non-motor Symptoms in Parkinson's Disease | 2026-12-31 |
| NCT07422675Serina TherapeuticsSAD Study in Patients With Parkinson's Disease and Motor Fluctuations | 2027-01-31 |
| NCT07172295National Taiwan University HospitalModulate Tremor Severity With Low-intensity Focused Ultrasound Stimulation Targeting the Deep Nucleus of Patients With Refractory Hand Tremor. | 2027-06-30 |
| NCT07028515National Taiwan University HospitalSelf-controlled Practice on Motor Learning and Motivation in Parkinson's Disease | 2027-07-31 |
| NCT07294469Taipei Medical University HospitalMenthol for Improving Movement and Sleep in Parkinson's Disease Patients | 2027-07-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 121 studies in Parkinson Disease with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-center, non-randomized study to assess the efficacy of Clostridium Butyricum Miyairi on the motor and non-motor symptoms of Parkinson's disease
The physician will explain the trial procedures in the outpatient, and then obtain the written informed consent to start the interview. And randomly divided into experimental and observation groups, and according to the timing of taking Miyarisan, scale evaluation and sample collection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year, then stopped for 1 year
Drug: Miyarisan-BM (Clostridium Butyricum Miyairi)
observation for 1 year and then Miyarisan-BM (Clostridium Butyricum Miyairi) for 1 year.
Drug: Miyarisan-BM (Clostridium Butyricum Miyairi)
probiotics
MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part 3
Part 3 of this scale assesses motor performance in 33 items. Each item is scored on a scale of 0 (normal) to 4 (severe), with a total score range of 0 to 132, and higher scores mean the patient's situation is worse.
Time frame: 0, 3, 12, 15, 24 months
Hamilton Depression Rating Scale (HAM-D)
This scale assesses non-motor symptoms in 17 items, the total scale value is 50 (Scores 0 to 7 mean normal, 8 to 13 mean mild depression, 14 to 18 mean moderate depression, 19 to 22 mean severe depression, and ≥23 mean very severe depression).
Time frame: 0, 3, 12, 15, 24 months
Hamilton Anxiety Scale (HAM-A)
This scale assesses non-motor symptoms in 14 items. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where ≤17 indicates mild anxiety severity, 18-24 indicate mild to moderate anxiety severity, 25-30 indicate moderate to severe anxiety severity, \>30 indicate severe anxiety.
Time frame: 0, 3, 12, 15, 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 38 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kaohsiung Medical University Chung-Ho Memorial Hospital →